These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36969182)

  • 21. Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation.
    Fujiwara H
    Front Immunol; 2021; 12():703298. PubMed ID: 34512627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graft-versus-host disease management.
    Mistrik M; Bojtarova E; Sopko L; Masakova L; Roziakova L; Martinka J; Batorova A
    Bratisl Lek Listy; 2016; 117(7):388-96. PubMed ID: 27546540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Disruption of gut immune system caused by damage of intestinal stem cells and their niche in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.].
    Hayase E; Teshima T
    Clin Calcium; 2017; 27(6):829-833. PubMed ID: 28536321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
    Ara T; Hashimoto D
    Front Immunol; 2021; 12():713631. PubMed ID: 34512636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.
    Li J; Zhang X; Chen Y; Zheng Q; Zhao M; Jiang H
    Oxid Med Cell Longev; 2022; 2022():2124627. PubMed ID: 35571252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between oral and fecal microbiome dysbiosis and treatment complications in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Faraci M; Bonaretti C; Dell'Orso G; Pierri F; Giardino S; Angiero F; Blasi S; Farronato G; Di Marco E; Trevisiol A; Olcese E; Rufino L; Squillario M; Biassoni R
    Sci Rep; 2024 Mar; 14(1):6708. PubMed ID: 38509104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation.
    Malard F; Jenq RR
    Cancer J; 2023 Mar-Apr 01; 29(2):75-83. PubMed ID: 36957977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omitting Ciprofloxacin Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Clinical Outcomes and Microbiome Structure.
    Daoud-Asfour H; Henig I; Ghersin I; Rakedzon S; Stern A; Pitashny M; Zuckerman T; Bar-Yoseph H
    Transplant Cell Ther; 2022 Mar; 28(3):168.e1-168.e8. PubMed ID: 34954293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children.
    Wetzel L; Wittig S; Gruhn B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):255-265. PubMed ID: 34120222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
    van Lier YF; Vos J; Blom B; Hazenberg MD
    Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The composition of the intestinal microbiota after allogeneic haematopoietic stem cell transplantation and its association with graft versus host disease as assessed by 16Sribosomal ribonucleic acid.
    Li DS; Wu YR; Du WH; Zhu YL; Zhang WJ; Fu Y; Yang GB
    J Physiol Pharmacol; 2023 Feb; 74(1):. PubMed ID: 37245237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal relationship between the gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) following pediatric allogeneic hematopoietic cell transplantation (HCT) - Case series.
    Gray AN; Tobin NH; Moore TB; Li F; Aldrovandi GM
    Int J Med Microbiol; 2023 May; 313(3):151580. PubMed ID: 37121094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal Microbiota Transplantation for Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Expanding the Horizon into Pediatrics.
    Gray AN; DeFilipp Z
    Transplant Cell Ther; 2023 Aug; 29(8):484-491. PubMed ID: 37169290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of GVHD on the gut and intestinal microflora.
    Ji H; Feng S; Liu Y; Cao Y; Lou H; Li Z
    Transpl Immunol; 2024 Feb; 82():101977. PubMed ID: 38184214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [GVHD: pathophysiology and novel agents].
    Ara T; Hashimoto D
    Rinsho Ketsueki; 2022; 63(9):1261-1269. PubMed ID: 36198552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
    Rayasam A; Drobyski WR
    Front Immunol; 2021; 12():779076. PubMed ID: 34899738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
    Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
    Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.